Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster-Reference-Cited by-同舟云学术

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster

Published:2023-12 Issue: Volume:98 Page:104878
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Nolan Terry M.^ORCID,Deliyannis Georgia,Griffith Maryanne,Braat Sabine^ORCID,Allen Lilith F.,Audsley Jennifer,Chung Amy W.,Ciula Marcin,Gherardin Nicholas A.,Giles Michelle L.,Gordon Tom P.,Grimley Samantha L.,Horng Lana,Jackson David C.,Juno Jennifer A.^ORCID,Kedzierska Katherine,Kent Stephen J.^ORCID,Lewin Sharon R.,Littlejohn Mason,McQuilten Hayley A.,Mordant Francesca L.,Nguyen Thi H.O.,Soo Vanessa Pac,Price Briony,Purcell Damian F.J.,Ramanathan Pradhipa^ORCID,Redmond Samuel J.^ORCID,Rockman Steven,Ruan Zheng,Sasadeusz Joseph,Simpson Julie A.,Subbarao Kanta,Fabb Stewart A.,Payne Thomas J.,Takanashi Asuka,Tan Chee Wah,Torresi Joseph,Wang Jing Jing,Wang Lin-Fa,Al-Wassiti Hareth,Wong Chinn Yi,Zaloumis Sophie,Pouton Colin W.^ORCID,Godfrey Dale I.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference38 articles.

1. Detection of a SARS-CoV-2 variant of concern in South Africa;Tegally;Nature,2021

2. Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant;Madhi;N Engl J Med,2021

3. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa;Viana;Nature,2022

4. Antibody response to omicron BA.4–BA.5 bivalent booster;Wang;N Engl J Med,2023

5. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity;Richardson;Cell Rep Med,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection;Nature Communications;2024-02-02